Supernus Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US8684591089

SecuritySUPN / Supernus Pharmaceuticals, Inc.
InstitutionNatixis Advisors, L.p.
Latest Disclosed Ownership27,760 shares
Latest Disclosed Value $ 1,435
Natixis Advisors, L.p. reports 13.80% increase in ownership of SUPN / Supernus Pharmaceuticals, Inc.

On May 13, 2026 - Natixis Advisors, L.p. filed a 13F-HR form disclosing ownership of 27,760 shares of Supernus Pharmaceuticals, Inc. (US:SUPN) valued at $1,434,914 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 24,394 shares of Supernus Pharmaceuticals, Inc.. This represents a change in shares of 13.80% during the quarter. The current value of the position is $1,222,412 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 27,760 3,366 13.80 1 0.00 0.0020
2026-02-10 2025-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 24,394 125 0.52 1 0.00 0.0017
2025-11-13 2025-09-30 13F SUPERNUS PHARMACEUTICALS INC COM 868459108 24,269 -18,239 -42.91 1 0.00 0.0017
2025-08-13 2025-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 42,508 2,117 5.24 1 0.00 0.0021
2025-05-08 2025-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 40,391 1,324 3.39 1 0.00 0.0024
2025-02-10 2024-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 39,067 -251 -0.64 1 0.00 0.0026
2024-11-06 2024-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 39,318 5,113 14.95 1 0.0024
2024-08-01 2024-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 34,205 -3,676 -9.70 1 -100.00 0.0020
2024-04-25 2024-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 37,881 1,122 3.05 1 0.00 0.0030
2024-02-06 2023-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 36,759 1,081 3.03 1 0.0028
2023-11-13 2023-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 35,678 1,647 4.84 1 -100.00 0.0030
2023-08-15 2023-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 34,031 -2,713 -7.38 1 0.00 0.0032
2023-05-11 2023-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 36,744 1,194 3.36 1 0.00 0.0046
2023-01-27 2022-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 35,550 755 2.17 1 -99.92 0.0048
2022-11-14 2022-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 34,795 1,497 4.50 1,178 22.33 0.0050
2022-08-12 2022-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 33,298 2,172 6.98 963 -4.27 0.0042
2022-05-12 2022-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 31,126 4,129 15.29 1,006 27.83 0.0038
2022-02-08 2021-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 26,997 4,953 22.47 787 33.84 0.0030
2021-11-15 2021-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 22,044 2,419 12.33 588 -2.65 0.0024
2021-08-12 2021-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 19,625 3,525 21.89 604 43.47 0.0028
2021-05-05 2021-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 16,100 -96 -0.59 421 3.44 0.0022
2021-02-12 2020-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 16,196 3,774 30.38 407 57.14 0.0023
2020-11-12 2020-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 12,422 -1,623 -11.56 259 -22.46 0.0016
2020-08-11 2020-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 14,045 14,045 334 0.0022
2020-04-27 2020-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 0 -52,152 -100.00 0 -100.00
2020-02-10 2019-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 52,152 -12,793 -19.70 1,237 -30.70 0.0087
2019-11-12 2019-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 64,945 -14,932 -18.69 1,785 -32.46 0.0142
2019-08-12 2019-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 79,877 79,877 2,643 0.0216
2017-02-07 2016-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 0 -25,746 -100.00 0 -100.00
2016-11-04 2016-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 25,746 2,045 8.63 637 31.88 0.0083
2016-08-01 2016-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 23,701 23,701 483 0.0067
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.